NKTR - Nektar Therapeutics

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
41.69
-0.93 (-2.18%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close42.62
Open43.15
Bid42.25 x 800
Ask42.48 x 1400
Day's Range40.05 - 43.30
52 Week Range29.22 - 111.36
Volume2,894,375
Avg. Volume2,016,664
Market Cap7.216B
Beta (3Y Monthly)3.74
PE Ratio (TTM)9.73
EPS (TTM)4.28
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est78.89
Trade prices are not sourced from all markets
  • Reuters11 hours ago

    Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

    Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study. Of the 27 patients with urothelial cancer, 19 percent showed complete response after being treated with the combo therapy using Nektar's NKTR-214, according to data, which was presented at the Genitourinary Cancers Symposium in San Francisco. The disease, which can infect any part of the urinary tract including the renal pelvis and the bladder, is the sixth most common type of cancer in the United States, the company said.

  • PR Newswire11 hours ago

    Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium

    Analyst conference call with urothelial cancer specialist to be held at 2:00 p.m. Pacific Time today SAN FRANCISCO , Feb. 15, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation ...

  • GlobeNewswire19 hours ago

    Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • 8 Stocks That Can Lead in a 'Micro-Driven' Market
    Investopedia2 days ago

    8 Stocks That Can Lead in a 'Micro-Driven' Market

    Morgan Stanley expects stock returns to be driven primarily by company-specific factors in the near-term.

  • 9 U.S. Stocks That Are Coming to Life Again
    InvestorPlace3 days ago

    9 U.S. Stocks That Are Coming to Life Again

    This year has been an unusually bullish one for U.S. stocks. Granted, the market started 2019 with the advantage of a steep selloff during the final three months of last year, setting up a big bounce out of an oversold condition. Traders remain confident at current levels, however, not flinching at the first whiff of potential trouble.The S&P 500's 15% advance from the late-December low hasn't just put the broad market back into a bullish mode, however. It has yanked some stocks out of a rut and back into an uptrend as well. In many of those cases, that turnaround coincides with a fundamental turnaround from the company itself. * Buy These 5 Stocks to Play the Megatrend of the Century With that as the backdrop, here's a rundown of the nine best U.S. stocks to plug into for a turnaround effort. All of them have made good forward progress, developing some momentum as a result. A closer read of their respective headlines also reveals the much-needed rhetoric has taken a turn for the better, reflective of fresh profit growth, sales growth or both.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn no particular order… Snap (SNAP)Some investors had altogether given up on Snapchat parent Snap (NYSE:SNAP), convinced there just wasn't room for a third social media name in an environment that included Facebook (NASDAQ:FB) and Twitter (NYSE:TWTR). SNAP stock, between its February 2017 high hit shortly after its IPO and its low in December of last year, lost more than 80% of its value, while slowing user growth finally turned negative in the middle of 2018.A glimmer of hope started to shine during the final quarter of last year. Its daily user total stabilized, and the habitual losses finally began to shrink.It's far from an ironclad turnaround, but it has been enough to spark over a 70% rebound from its December low. Coty (COTY)Like Snap, beauty company Coty (NYSE:COTY) is a name many investors had given up on. Shares fell 80% between early 2016 and the end of last year, mostly in response to an uninterrupted streak of declining revenue and shrinking profits.It's another name, however, that may have turned a corner nobody was expecting it to. COTY stock is up nearly 80% since its late December low, with most of that gain spurred by last quarter's revenue and earnings. Both topped estimates. * 10 Best Dividend Stocks to Buy for the Next 10 Months Bonus: Several new executives -- including a new CFO -- have been named, setting the stage for some much-needed change in how the organization is managed. Bolstering the bullish argument is this week's report that JAB Holding Co. is looking to take on a major equity stake in COTY stock at its current price. Zynga (ZNGA)Yes, the name behind popular casual gaming titles like Farmville, Words with Friends and Mafia Wars is still alive and kicking, even though its top games have largely run their course. In fact, Zynga (NASDAQ:ZNGA) CEO Frank Gibeau recently stated "Zynga's turnaround is now complete," referencing last year's 5% improvement in revenue, leading into more earnings growth for this year.The key has been a successful transition to mobile. Mobile engagement now make up more than 90% of game-play sessions, and Zynga has made a point of developing or acquiring the right games to engage players where they want to play. Its purchase of Gram and Small Giant gave it Merge Dragons and Empire of Puzzles, respectively, and both have been needed hits.ZNGA stock is up 24% year-to-date after a lackluster 2018. Nektar Therapeutics (NKTR)Despite Tuesday's 9% setback, Nektar Therapeutics (NASDAQ:NKTR) shares are still up over 25% for the year so far, unwinding what has been a pretty miserable past few months.The stock's budding turnaround was largely prompted by hope for major progress this year. At the J.P. Morgan Healthcare conference held very early this year, Nektar announced several ambitious goals for the year, including the potential release of an abuse-deterrent opioid painkiller. * 7 Reasons You Want Boeing Stock in Your Portfolio Investors also gave the company a little credit for the launch of a couple early-stage trials of autoimmune drug NKTR-358, which has drawn the interest of Eli Lilly (NYSE:LLY). Though its NKTR-214 looks to be a bust as a means of improving PD-1 treatments, the market may be thinking it treated NKTR stock too harshly in response. Copart (CPRT)Copart (NASDAQ:CPRT) isn't exactly a household name, though it may have a place in some portfolios.The company is predominantly an automobile auction outfit, able to handle sales of fleet vehicles as well as it can offload cars for individuals. It's especially well known as a buyer of junked or un-drivable cars and a seller of salvageable parts.It's an interesting business. Whereas automobile manufacturers like Ford Motor (NYSE:F) or General Motors (NYSE:GM) are now facing the downside of 2015's so-called "peak auto," in many regards that's proven beneficial for Copart. The cars those drivers replaced had to be dealt with somehow, and given that most of Copart's auctions are consigned auctions, the company has a plentiful, low-to-no cost supply of inventory. Mostly though, it's a non-cyclical business that's expected to grow revenue by 10% this year.CPRT stock may only be up about 10% so far this year, but it was one of the hardest-hit U.S. stocks during the fourth quarter. That leaves plenty of room for more recovery. Dentsply Sirona (XRAY)Dentsply Sirona (NASDAQ:XRAY) is a manufacturer of equipment and supplies for the dentistry industry … a boring lineup that has been reasonably consistent (even if not perfect) in terms of revenue growth.That reliability did the stock little good for the better part of last year. Between its January high and October low, XRAY stock was cut in half, primarily due to deteriorating revenue and profits that most investors didn't expect. By the time all was said and done, shares reached a seven-year low in the latter part of last year. * 10 Monster Growth Stocks to Buy for 2019 and Beyond Though some degree of selling was certainly understandable, the bears arguably overshot. The 26% rebound since the end of October says investors are correcting their mistake in front of what should be a turnaround year. Analysts are only calling for about 2% sales growth in 2019, but that should be enough to improve per-share profits by 11%. Chipotle Mexican Grill (CMG)There was a time not too long ago when investors and consumers were wondering if Chipotle Mexican Grill (NYSE:CMG) would ever shrug off the impact of its 2015 E. coli debacle. Consumers were anything but quick to forget and forgive.Last quarter's results, however, suggest the new mix of management may be just what the struggling Tex-Mex eatery needed. Same-store sales improved 6.1%, while total revenue grew 10% thanks to store openings. Perhaps most compelling of all, however, was the earnings beat. Analysts were calling for a profit of $1.37 per share, but Chipotle reported income of $1.72 per share.There's still work to be done, to be sure. But, the work that's been done so far has been enough to drive CMG stock to a 40% gain since the end of last year. Bausch Health Companies (BHC)Bausch Health Companies (NYSE:BHC) has had a surprisingly tough past three years, although most of that pain played out while it was still called Valeant Pharmaceuticals … the company that racked up too much debt buying small-market drugs only to find political and societal pushback on its aggressive pricing policies at the worst possible time. With the proverbial party abruptly coming to a close in late 2015, Valeant shares lost roughly 97% of their value between July of 2015 and mid-2017.It's curious though. With very little fanfare despite measurable (albeit slow) fiscal progress, BHC stock has made nothing but higher lows and higher highs since the middle of 2017. * The 9 Best Stocks to Invest In During a Manic Market The 47% gain from its December low is exaggerated thanks to the steep pullback preceding that reversals, but the bullish high-low pattern has become pretty reliable. Foot Locker (FL)By the middle of 2017, the athletic apparel industry -- and the athletic shoe industry in particular -- was in trouble. Celebrity endorsements had become gratuitous and expensive, peaking right as consumers grew tired of paying big prices just to wear the same sneakers that stars like Kevin Durant and LeBron James wear.Mike Packer, owner of Packer Shoes, explained the then-brewing dilemma a year earlier, saying "Over the last two years, companies have taken retro basketball and in-line product and spun off too many colors, too many stories. … Some of these models are being brought to market for their third or fourth time. It loses the allure."The shift took its toll on Foot Locker (NYSE:FL) stock. Shares tumbled more than 60% in 2017.Things have been different in the meantime, however. Realizing it has to get back to basics and work strategically with key suppliers like Nike (NYSE:NKE), the retailer has hammered out enough improvements to drive a 20% gain from its December low. That latest bullish leg extends a quiet winning streak that now goes back a full year.As of this writing, James Brumley held a long position in Foot Locker. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks That Every 20-Year-Old Should Buy * 10 Best Dividend Stocks to Buy for the Next 10 Months * 10 Monster Growth Stocks to Buy for 2019 and Beyond Compare Brokers The post 9 U.S. Stocks That Are Coming to Life Again appeared first on InvestorPlace.

  • Benzinga4 days ago

    The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 11) Boston Scientific Corporation (NYSE: BSX ) Inspire ...

  • PR Newswire4 days ago

    Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium

    SAN FRANCISCO , Feb. 11, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company ...

  • Why Nektar Therapeutics Stock Gained 29% in January
    Motley Fool4 days ago

    Why Nektar Therapeutics Stock Gained 29% in January

    The biotech company clawed back some of 2018's losses in the first month of the new year.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Nektar Therapeutics.

    Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding NKTR totaled $16.06 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Mizuho's 9 Best Biotech Stocks to Buy for 2019
    Kiplinger10 days ago

    Mizuho's 9 Best Biotech Stocks to Buy for 2019

    Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • 5 "Strong Buy" Stock Picks for 2019 (That Crashed in 2018)
    Kiplinger20 days ago

    5 "Strong Buy" Stock Picks for 2019 (That Crashed in 2018)

    Which of 2018's losers are poised for big gains in 2019? There's certainly no shortage of stocks to pick from. The major indices all suffered losses in 2018, with hundreds of their components (and several thousand more stocks on top of that) bleeding red ink by year's end. But how do you sort the promising stocks that can rebound from stocks whose falls were justified (and continue declining more)? One way is to examine what the financial experts are saying. In this case, we used TipRanks' Top Analyst Stocks tool to pinpoint five stocks with a bullish "Strong Buy" analyst consensus rating. This is based on all the ratings a stock receives over the past three months. Here are five "Strong Buy" stock picks for 2019, based on analysts' bullishness for the 12 to 18 months ahead. What makes them even more attractive is the relative discounts they're trading at following 2018's selloff. ### SEE ALSO: 11 Great Stocks to Buy and Hold for the Next Decade

  • Is Bristol-Myers Squibb a Bargain Now?
    Motley Fool21 days ago

    Is Bristol-Myers Squibb a Bargain Now?

    The big pharma stock has taken a pounding for good reasons, but it looks like the punishment has gone too far.

  • These beaten-down stocks are expected to roar back in 2019
    MarketWatchlast month

    These beaten-down stocks are expected to roar back in 2019

    Dozens of favored S&P 500 stocks have suffered declines of more than 20% since the end of the third quarter.

  • Here's Why Nektar Therapeutics Gave Back 45% in 2018
    Motley Foollast month

    Here's Why Nektar Therapeutics Gave Back 45% in 2018

    Last year started out with a bang, but the excitement didn't last very long.

  • Here's Why Nektar Therapeutics Surged Today
    Motley Foollast month

    Here's Why Nektar Therapeutics Surged Today

    Investors liked what the company had to say about the year ahead.

  • Investing.comlast month

    Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close

    Investing.com - Union Pacific , Motorcar Parts of America and Nektar Therapeutics surged on Tuesday, underpinning a second-straight day of gains in the broader market.

  • A Look at Sarepta Therapeutics’ Recent Developments
    Market Realistlast month

    A Look at Sarepta Therapeutics’ Recent Developments

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year. In the third quarter of 2018, the company reported net income and EPS of -$76.4 million and -$1.15, respectively, compared to -$47.7 million and -$0.78 in the third quarter of 2017. Wall Street analysts anticipate that in the fourth quarter of 2018, Sarepta Therapeutics will report net income and EPS of -$63.26 million and -$0.95, respectively. Analysts also estimate that the company will report net income and EPS of -$274.73 million and -$4.16, respectively, in fiscal 2018. Wall Street analysts estimate that BioMarin Pharmaceuticals (BMRN), Nektar Therapeutics (NKTR), and Vertex Pharmaceuticals (VRTX), Sarepta Therapeutics’ peers in the biopharmaceuticals market, will report EPS of around -$0.62, $3.88, and $2.88, respectively, in fiscal 2018. ## Recent developments On January 2, 2019, Sarepta Therapeutics entered a long-term strategic relationship with Aldevron. Aldevron is one of the leading producers of custom proteins, nucleic acids, and antibodies for use in the biotech industry. As per the terms of the agreement, Aldevron will supply plasmid DNA for the fulfillment of Sarepta Therapeutics’ requirements in its gene therapy clinical trials and commercial purposes. Aldevron will specifically supply GMP-grade plasmid for Sarepta Therapeutics’ micro-dystrophin Duchenne muscular dystrophy (or DMD) and Limb-girdle muscular dystrophy (or LGMD) gene therapy programs. As per the terms of the agreement, Aldevron will also supply plasmid for Sarepta Therapeutics’ future gene therapy programs. The agreement is expected to help Sarepta Therapeutics with sufficient plasmid for research and commercial purposes. Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 2 - How Is Sarepta Therapeutics Positioned in January?

  • How Is Sarepta Therapeutics Positioned in January?
    Market Realistlast month

    How Is Sarepta Therapeutics Positioned in January?

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million. In the third quarter of 2018, the company’s revenue grew ~71% YoY to $78.5 million from $46.0 million. Wall Street analysts estimate that Sarepta Therapeutics will generate revenues of $85.8 million in the fourth quarter of 2018. Analysts also estimate that the company’s net revenue in fiscal 2018 will be around $301.1 million, which represents ~49.9% YoY growth. In the third quarter of 2018, Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN), Sarepta Therapeutics’ peers in the biopharmaceuticals market, reported revenues of $27.8 million, $783.9 million, and $391.7 million, respectively, which represents a ~81.9% YoY decline, a ~42.04% YoY increase, and a ~17.23% YoY increase. Wall Street analysts estimate that Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN) will generate revenues of $1.2 billion, $3.0 billion, and $1.5 billion, respectively, which represents ~289%, ~37.41%, and ~15% YoY growth. ## Expense trends In the first nine months of 2018, Sarepta Therapeutics’ cost of sales excluding amortization of in-licensed rights amounted to $21.1 million compared to $3.8 million in the same period the prior year. In the first nine months of 2018, Sarepta Therapeutics reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $255.6 million and $143.5 million, respectively, compared to $122.3 million and $90.5 million in the same period the prior year. Wall Street analysts estimate that Sarepta Therapeutics will report cost of sales, SG&A, and R&D expenses of $30.2 million, $190.88 million and $317.02 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • Sarepta Therapeutics Stock Rose 96% in 2018
    Market Realistlast month

    Sarepta Therapeutics Stock Rose 96% in 2018

    Who Is Eyeing Sarepta Therapeutics Now? ## Stock performance On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its close of $106.67 on January 3. Sarepta Therapeutics stock grew from $55.64 at the close of market on December 29, 2017, to reach $109.13 at the close of market on December 31, 2018, which represents ~96% growth over 2018. On January 2, 2019, Sarepta Therapeutics stock closed at $107.50, which is ~35% below its 52-week high of $176.50 on June 19, 2018. The company hit its 52-week low of $26.26 on February 13, 2018. ## Recent developments In December 2018, Sarepta Therapeutics (SRPT) completed the submission of its continuing NDA (new drug application) that seeks approval of its golodirsen for the treatment of individuals with Duchenne muscular dystrophy with genetic mutations associated to skipping exon 53 Duchenne gene. Sarepta Therapeutics’ golodirsen is an engineered phosphorodiamidate morpholino oligomer for the treatment of DMD with genetic mutations of skipping exon 53 of the DMD gene. ## Analyst recommendations Of the 24 analysts tracking Sarepta Therapeutics in January 2019, nine of them recommended a “strong buy,” while 14 analysts recommended a “buy” rating. One analyst recommended a “hold” for Sarepta Therapeutics in January. On January 7, Sarepta Therapeutics had a consensus 12-month target price of $194.36, which represents a ~68.38% return on investment over the next 12-months. ## Peers’ ratings In January 2018, of 27 analysts tracking BioMarin Pharmaceuticals (BMRN), ~78% of them recommended “buys.” Of the 11 analysts tracking Exelixis (EXEL), ~73% of them recommended “buys.” Of the 11 analysts tracking Nektar Therapeutics (NKTR), ~82% of them recommended “buys.” On January 7, BioMarin Pharmaceuticals (BMRN), Exelixis (EXEL), and Nektar Therapeutics (NKTR) had a consensus 12-month target price of $120.3, $28.78, and $78.89, respectively, which represents ~38.12%, ~38.83%, and a ~132.30% return on investment over the next 12 months. Continue to Next Part Browse this series on Market Realist: * Part 2 - How Is Sarepta Therapeutics Positioned in January? * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Celgene and Nektar Therapeutics

    The Dow Jones Industrial Average gained 0.08 percent to close at 23,346.24, while the S&P 500 Index increased 0.13 percent to close at 2,510.03. The Nasdaq Composite Index climbed 0.46 percent to close at 6,665.94. Celgene’s stock jumped 3.98% Wednesday, to close the day at $66.64.

  • ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics
    PR Newswirelast month

    ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics

    Nektar will use ImaginAb's CD8 ImmunoPET technology to accelerate the development of its investigational immuno-oncology medicines LOS ANGELES , Jan. 3, 2019 /PRNewswire/ -- ImaginAb Inc., an immuno-oncology ...

  • Business Wire2 months ago

    DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • GlobeNewswire2 months ago

    CLASS ACTION UPDATE for NKTR, FIT, WBT and XRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.